Paradigm Biopharmaceuticals (ASX:PAR) has key milestone news flow pending.
The company is fully-funded through to the completion of the Phase 2 open label clinical trial for bone bruising, Phase 2 hay fever and Phase 2 alpha viruses trials.
The results have the potential to generate interest from Big Pharma.
Find out more from Paul Rennie at Proactive's CEO Sessions.
Click below to register
- Paradigm Biopharmaceuticals (ASX:PAR): CEO Paul Rennie
- Stonewall Resources (ASX:SWJ): MD Robert Thomson
- White Rock Minerals (ASX:WRM): MD Matthew Gill
- The Hydroponics Company (ASX:THC): CEO (medicinal Cannabis division, Canndeo) Andrew Beehag
Final company to be added to the roster